Improved Small Extracellular Vesicle Secretion of Rat Adipose-Derived Stem Cells by Microgrooved Substrates through Upregulation of the ESCRT-III-Associated Protein Alix.
Ji Y., Han W., Fu X., Li J., Wu Q., Wang Y.
Animal Study, published in Adv Healthc Mater (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Adv Healthc Mater (2021)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 34176241
- DOI
- 10.1002/adhm.202100492
- Citations
- 10
Abstract (original English)
Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) hold great potential for regenerative therapies and have received considerable research attention in recent years. However, the use of MSC-sEVs is limited by very low yield in routine culture conditions and suboptimal potency for certain diseases. Thus, strategies that enable the production of sufficient quantities of sEVs with desired therapeutic cargo in a facile and inexpensive way are in high demand. This study finds that the microgrooved substrates stimulate rat adipose-derived mesenchymal stem cells (rASCs) to produce a larger quantity of sEVs than the flat substrates. Further investigation suggests that the ESCRT-III-associated protein Alix may be involved in mediating the elevated sEV production of rASCs on the microgrooved substrates. Besides, the cargo of sEVs is altered. SEVs secreted by rASCs on the microgrooved substrates carry higher levels of proangiogenic miRNAs and growth factors than those secreted by rASCs on the flat substrates. Functional assessments demonstrate that sEVs from rASCs on microgrooved substrates enhance the angiogenic properties of Human umbilical vein endothelial cells. The findings demonstrate that substrate topography is an effective regulator of the sEVs secretion by rASCs and highlight the potential of using microgrooved substrates as a platform to produce rASC-sEVs ric
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.